Stoke Therapeutics, Inc. (NASDAQ: STOK) is a Healthcare company (Biotechnology) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Stoke Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $26.41, Stoke Therapeutics, Inc. trades at 61.1x sales and 5.1x book value. Over the last twelve months it generated about $28M of revenue and a net loss of $248M. It runs a gross margin of 88.5%, an operating margin of -913.1% and a net margin of -862.1%. It shows return on equity of -67.3%, return on invested capital of -72.0% and a free cash flow yield of -12.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.24. Over the past 52 weeks the share price ranged from $22.05 to $40.22, with a beta of 1.38.
Stoke Therapeutics, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 13 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.